Evidence map›Paper›PMID 33452614›Full record

ArticleMedical oncology (Northwood, London, England)2021

The relationship between eGFR and capecitabine efficacy/toxicity in metastatic breast cancer.

Emir Celik, Nilay Sengul Samanci, Mehmet Karadag, Nebi Serkan Demirci, Fuat Hulusi Demirelli, Mustafa Ozguroglu

Abstract read
PubMed Publisher
In one paragraph

Article in Medical oncology (Northwood, London, England), 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact, top 99% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 0 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

Emir CelikCerrahpaşa Faculty of Medicine, Department of Medical Oncology, Istanbul University-Cerrahpaşa, Kocamustafapasa Cd. No:53 Cerrahpasa, 34098, Fatih/Istanbul, Turkey. emircelikk@gmail.com.ORCID http://orcid.org/0000-0001-8440-3082
Nilay Sengul SamanciCerrahpaşa Faculty of Medicine, Department of Medical Oncology, Istanbul University-Cerrahpaşa, Kocamustafapasa Cd. No:53 Cerrahpasa, 34098, Fatih/Istanbul, Turkey.
Mehmet KaradagFaculty of Medicine, Department of Biostatistics, Hatay Mustafa Kemal University, Antakya, Turkey.
Nebi Serkan DemirciCerrahpaşa Faculty of Medicine, Department of Medical Oncology, Istanbul University-Cerrahpaşa, Kocamustafapasa Cd. No:53 Cerrahpasa, 34098, Fatih/Istanbul, Turkey.
Fuat Hulusi DemirelliCerrahpaşa Faculty of Medicine, Department of Medical Oncology, Istanbul University-Cerrahpaşa, Kocamustafapasa Cd. No:53 Cerrahpasa, 34098, Fatih/Istanbul, Turkey.
Mustafa OzgurogluCerrahpaşa Faculty of Medicine, Department of Medical Oncology, Istanbul University-Cerrahpaşa, Kocamustafapasa Cd. No:53 Cerrahpasa, 34098, Fatih/Istanbul, Turkey.
Istanbul University-Cerrahpaşa · TRMustafa Kemal University · TR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The objective of this study was to evaluate the efficacy and toxicity of capecitabine in metastatic breast cancer (mBC) according to the estimated glomerular filtration rate (eGFR). A total of 135 patients included in the final analysis were stratified into 3 categories according to baseline eGFR, i.e., eGFR <60 mL/min/1.73 m

Indexed as

AdultAgedAntimetabolites, AntineoplasticBreast NeoplasmsCapecitabineDrug-Related Side Effects and Adverse ReactionsDrug TaperingFemaleGlomerular Filtration RateHumansMiddle AgedTreatment OutcomeAntimetabolites, AntineoplasticCapecitabineBreast cancerCapecitabineRenal insufficiencyToxicity

Identifiers

PMID33452614
OpenAlexW3125580730

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.